Investor interest in gene therapy has declined sharply, with venture funding dropping and some companies like Pfizer pulling back, as attention shifts to higher-growth areas like obesity and cancer. Data from DealForma highlights the steep funding drop, while industry experts point to manufacturing challenges, high costs, and evolving regulatory needs as barriers that must be overcome for a rebound. Read the article here
